Treatment of metastatic testicular tumours with bleomycin, etoposide, cisplatin and vincristine (BEPV).
Between August 1983 and December 1988, 47 patients with metastatic testicular tumours (44 non-seminomatous, three seminomas) were treated with two to six courses of bleomycin, etoposide, cisplatin and vincristine (BEPV). Five stage I tumours were included, three because of raised tumour markers following orchidectomy, one with vascular invasion of spermatic cord vessels and the other with both these features. Forty-four patients (93.6%) are alive and disease free 12-75 months (median 39 months) after completion of BEPV. Further treatment was necessary in 12 of the survivors. Eight had residual disease excised, one of whom received radiotherapy, one additional chemotherapy and one both radiotherapy and chemotherapy. Of the remaining four, two had radiotherapy and two second line chemotherapy. Thirty-one non-seminomatous and the three seminoma patients had small volume disease and all are in complete remission. Ten of the 13 patients with bulky disease are alive. It is concluded that BEPV is a well-tolerated, effective, first line therapy for patients with metastatic testicular tumour.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin; D002945:Cisplatin; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D005047:Etoposide; D006801:Humans; D008297:Male; D013724:Teratoma / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000601:surgery; D014750:Vincristine
D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D002945:Cisplatin